FB Pixel no scriptChinese drug makers downplay US threat
MENU
KrASIA
Sep
12

Chinese drug makers downplay US threat

just now
Chinese pharmaceutical executives sought to reassure investors after a report said the US may restrict licensing deals for China-developed drugs. Shares of Hong Kong-listed firms fell, but at BioHK 2025, leaders from Grand Pharma, China Resources Pharma, CureGene, and Yunnan Baiyao said risks could be managed through diversification, regionalization, and overseas clinical trials.
Share

Latest Pulses

See All

Most Recent